Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing Protease Inhibitor ABT-450 to be Presented at the

  Enanta Pharmaceuticals Announces Data Presentations on Regimens Containing   Protease Inhibitor ABT-450 to be Presented at the European Association for   the Study of the Liver (EASL) Meeting  Business Wire  WATERTOWN, Mass. -- March 24, 2014  Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a research and development-focused biotechnology company dedicated to creating small molecule drugs in the infectious disease field, today announced eight studies have been accepted for presentation at the International Liver Congress (ILC), which is the 49th Annual Meeting of the European Association for the Study of the Liver (EASL) taking place in London April 9-12, 2014. These presentations will report results of regimens containing ABT-450, Enanta’s lead protease inhibitor for hepatitis C virus (HCV) identified in its ongoing collaboration with AbbVie. Abstracts can now be viewed at the EASL website at www.easl.eu.  Following is a list of ABT-450-related presentations:  Oral Presentations:    *SAPPHIRE-II: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week     Regimen of ABT-450/r/ABT-267, ABT-333 and Ribavirin in     Treatment-Experienced Adults with Hepatitis C Virus in Genotype-1     S. Zeuzem, et al., April 10, 2014, 14:00-14:15 BST   *Results from the Phase 2 PEARL-I Study: Interferon-Free Regimens of     ABT-450/r + ABT-267 with or without Ribavirin in Patients with HCV     Genotype 4 Infection     C. Hezode, et al., April 11, 2014, 09:45-10:00 BST   *SAPPHIRE-I: Phase 3 Placebo-Controlled Study of Interferon-Free, 12-Week     Regimen of ABT-450/r/ ABT-267, ABT-333 and Ribavirin in 631     Treatment-Naïve Adults with Hepatitis C Virus in Genotype-1     JJ Feld, et al., April 11, 2014, 10:15-10:30 BST   *Results of the Phase 2 Study of M12-999: Interferon-Free Regimen of     ABT-450/r/ABT-267+ABT-333+ Ribavirin in Liver Transplant Recipients with     Recurrent HCV Genotype 1 Infection     P. Kwo, et al., April 12, 10:15-10:30 BST  Poster Presentations:    *P783 – Serum MIR-122 May Serve as a Biomarker for Response to Direct     Acting Antivirals: Effect of ABT-450/r with ABT-333 or ABT-267 on MIR-122     in HCV-Infected Subjects     J.F. Waring, et al., April 11, 2014, 09:00 – 18:00 BST   *P1230 – Lack of Impact of Baseline Resistance- Associated Variants (RAVS)     on Treatment Outcome in the Aviator Study with ABT-450/r, ABT-333, and     ABT-267 +/- Ribavirin     P. Krishnan, et al., April 12, 2014, 09:00 – 18:00 BST  Late-Breaker Oral Presentation:    *TURQUOISE-II: SVR12 Rates of 92%-96% in 380 Hepatitis C Virus Genotype     1-Infected Adults with Compensated Cirrhosis Treated with     ABT-450/r/ABT-267 and ABT-333 plus Ribavirin (3D+RBV)     F. Poordad, et al. April 12, 2014, 15:30-15:45 BST  Late-Breaker Poster Presentation:    *P# 1299 – PEARL-III: 12 Weeks of ABT-450/r/267 + ABT-333 Achieved SVR in     >99% of 410 Treatment-Naïve HCV Genotype 1b-Infected Adults With or     Without Ribavirin     P. Ferenci, et al. April 12, 2014, 09:00-18:00 BST  About ABT-450  ABT-450 is an NS3 protease inhibitor discovered through Enanta’s collaboration with AbbVie. AbbVie and Enanta have an agreement to collaborate on the discovery, development and commercialization of HCV NS3 and NS3/4A protease inhibitors. Protease inhibitors play an essential role in the viral life cycle of the hepatitis C virus (HCV). Inhibition of the protease prevents non-structural (NS) proteins from forming and thereby prevents replication and survival of the HCV virus. ABT-450 is part of AbbVie’s investigational regimen for HCV that consists of boosted protease inhibitor ABT-450/ritonavir (referred to as ABT-450/r), NS5A inhibitor ABT-267 and non-nucleoside polymerase inhibitor ABT-333.  About Hepatitis C Virus (HCV)  Hepatitis C is a liver disease affecting over 170 million people worldwide. The virus is typically spread through direct contact with the blood of an infected person. Hepatitis C increases a person’s risk of developing chronic liver disease, cirrhosis, liver cancer and death. Patients with compensated cirrhosis have a liver that is heavily scarred but that can still perform many important bodily functions with few or no symptoms. There is an acute need for new HCV therapies that are safer and more effective for many variants of the virus.  About Enanta  Enanta Pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field. Enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis C virus (HCV). These inhibitors include members of the direct acting antiviral (DAA) inhibitor classes – protease (partnered with AbbVie), NS5A (partnered with Novartis) and nucleotide polymerase – as well as a host-targeted antiviral (HTA) inhibitor class targeted against cyclophilin. Additionally, Enanta has created a new class of antibiotics, called Bicyclolides, for the treatment of multi-drug resistant bacteria, with a focus on developing an intravenous and oral treatment for hospital and community MRSA (methicillin-resistant Staphylococcus aureus) infections.  Contact:  Investors Enanta Pharmaceuticals, Inc. Carol Miceli, 617-607-0710 cmiceli@enanta.com or Media MacDougall Biomedical Communications Kari Watson, 781-235-3060 kwatson@macbiocom.com  
Press spacebar to pause and continue. Press esc to stop.